Table 2.
Patient, tumor, and treatment characteristics (N=26)
| Characteristics |
Disease group [No. (%)] |
|
|---|---|---|
| NPC (n=10) | Others (n=16) | |
| Age (year) |
|
|
| Median |
54 |
58.5 |
| Range |
31-67 |
10-83 |
| Gender |
|
|
| Male:Female |
8 (80): 2 (20) |
12 (75): 4 (25) |
| Sites treated with SBRT |
|
|
| Nasopharynx and base of skull |
10 (100) |
|
| Nasal cavity and PNS |
|
8 (50) |
| Periorbit |
|
4 (25) |
| Tongue |
|
3 (18.8) |
| Oropharyngeal wall |
|
1 (6.2) |
| Pathology |
|
|
| Type I NPC |
2 (20) |
|
| Type II NPC |
8 (80) |
|
| Squamous cell carcinoma |
|
7 (43.8) |
| Adenoid cystic carcinoma |
|
5 (31.3) |
| Chondrosarcoma |
|
2 (12.5) |
| Malignant melanoma |
|
1 (6.2) |
| Poorly differentiated adenocarcinoma |
|
1 (6.2) |
| Tumor T stage |
|
|
| T4 |
7 (70) |
7 (43.8) |
| T3 |
2 (20) |
4 (25) |
| T2 |
1 (10) |
5 (31.2) |
| Tumor N stage |
|
|
| N2 |
3 (30) |
1 (6.3) |
| N1 |
6 (60) |
2 (12.5) |
| N0 |
1 (10) |
13 (81.2) |
| Previous debulking surgery |
|
|
| Yes:No |
0 (0):10 (100) |
11(68.8): 5 (31.2) |
| Combined chemotherapy |
|
|
| Yes:No |
10 (100): 0 (0) |
9 (56.3): 7 (43.7) |
| SBRT GTV (cc) |
|
|
| Median |
45.3 |
19.4 |
| Range |
21.3-69.4 |
6.9-66.8 |
| Prescription isodose line (%) |
|
|
| Median |
80 |
80 |
| Range |
70-80 |
70-85 |
| EBRT dose (Gy) |
|
|
| Median |
59.4 |
47.5 |
| Range |
50.4-70.2 |
39.6-59.4 |
| SBRT dose (Gy) |
|
|
| Median |
21 |
22.5 |
| Range |
18-25 |
10-25 |
| SBRT fractional dose (Gy) |
|
|
| Median |
6.5 |
5 |
| Range |
5-7 |
3-8 |
| Cumulative dose in BED10 (Gy) |
|
|
| Median |
103.7 |
90.6 |
| Range | 92-118.5 | 72.7-107.6 |
SBRT, stereotactic body radiotherapy; PNS, paranasal sinus; NPC, nasopharyngeal cancer; T, tumor; N, node; GTV, gross tumor volume; EBRT, external beam radiotherapy; BED10, biologically equivalent dose in α/β ratio of 10.